VivoSeq
Other

Recurrent NSCLC

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Recurrent NSCLC is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

67/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Terminated2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
Terminated·—·Phase 1·NCT00378404·10 enrolled
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Active, not recruiting·EEmory University·Phase 2·NCT04340882·30 enrolled
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00612677·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)